Zuzana Schlegel
Laser Vision Schlegel, Reunion Island
Title: Comparison of ranibizumab in monotherapy versus association with intravitreal dexamethasone in diabetic macular oedema
Biography
Biography: Zuzana Schlegel
Abstract
Introduction: To evaluate the efficacy of single intravitreal injections of ranibizumab compared with association with dexamethasone implant in diabetic macular oedema in anatomical, functional, safety and observance terms. Material and Methods: 60 patients suffering from diabetes mellitus were randomized into two groups. 30 patients received ranibizumab (R) injection as monotherapy, in three loading doses during first three months and thereafter depending on development of their visual acuity. Other 30 patients received, the simultaneous intravitreal injection of dexamethasone sustained-release implant (Ozurdex) with the first injection of ranibizumab (RD). The variation of BCVA and other criteria was observed monthly up to the twelve months. Results: The improvement of BCVA was superior in the combination treatment group RD than in monotherapy group R. The RD group patients gained 13 letters and the R group 10 letters, p = 0,031. The reduction of central retinal thickness was equally more important in the RD group, -177 μm, than in the R group, -127 μm, p < 0,001, compared to the income values, the chorioretinal atrophy was not remarked. Discussion: Up to this date there exists very few papers about the simultaneous administration of the two products, other than LuceDex study in the ARMD, whose results was also in favour of association of the intravitreal ranibizumab with dexamethasone implant. Conclusion: One year outcomes reveal the functional and anatomical superiority, safety and diminution of total number of interventions conducting in better observance, using combined RD intravitreal treatment versus single R monotherapy in diabetic macular edema.